<DOC>
	<DOCNO>NCT02698579</DOCNO>
	<brief_summary>This multi-center , long-term safety efficacy follow-up study subject cerebral adrenoleukodystrophy ( CALD ) receive Lenti-D Drug Product Study ALD-102 . After complete Study ALD-102 ( approximately 2 year ) , eligible subject follow additional 13 year total 15 year post-drug product infusion . No investigational drug product administer study .</brief_summary>
	<brief_title>Long-term Follow-up Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product</brief_title>
	<detailed_description />
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>Provision write informed consent study subject subject 's parent ( ) / legal guardian ( ) write informed assent subject , applicable Have receive LentiD Drug Product Study ALD102 Able comply study requirement . Met VCN discontinuation criterion Study ALD102 , follow : subject undetectable VCN ( &lt; 0.0003 copy per cell ) peripheral blood cell 2 consecutive measurement least 1 month apart least 12 month drug product infusion .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adrenoleukodystrophy</keyword>
	<keyword>X-linked Adrenoleukodystrophy</keyword>
	<keyword>Hematopoietic Stem Cells</keyword>
</DOC>